Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients

Affiliations

¹ The Francis Crick Institute, London NW1 1AT, UK.
² Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Department of Renal Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
³ Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴ Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
⁵ The Francis Crick Institute, London NW1 1AT, UK; UCL Dept of Renal Medicine, Royal Free Hospital, London, UK. Electronic address: rupert.beale@crick.ac.uk.

Comment

Edward J Carr et al. Lancet. 2022.

. 2022 Feb 26;399(10327):800-802.

doi: 10.1016/S0140-6736(22)00104-0. Epub 2022 Jan 20.

¹ The Francis Crick Institute, London NW1 1AT, UK.
² Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Department of Renal Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
³ Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴ Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK; Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
⁵ The Francis Crick Institute, London NW1 1AT, UK; UCL Dept of Renal Medicine, Royal Free Hospital, London, UK. Electronic address: rupert.beale@crick.ac.uk.

No abstract available

Figures

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
Carr EJ, Wu M, Harvey R, Wall EC, Kelly G, Hussain S, Howell M, Kassiotis G, Swanton C, Gandhi S, Bauer DL; Haemodialysis COVID-19 consortium; Crick COVID Immunity Pipeline; Billany RE, Graham-Brown MP, Beckett J, Bull K, Shankar S, Henderson S, Motallebzadeh R, Salama AD, Harper L, Mark PB, McAdoo S, Willicombe M, Beale R. Carr EJ, et al. Lancet. 2021 Sep 18;398(10305):1038-1041. doi: 10.1016/S0140-6736(21)01854-7. Epub 2021 Aug 13. Lancet. 2021. PMID: 34391504 Free PMC article. No abstract available.

1. UK Health Security Agency SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 33. Dec 23, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. Nature. 2022 doi: 10.1038/S41586-022-04411-y. published online Jan 7. - DOI - PMC - PubMed
1. The OpenSAFELY Collaborative Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. MedRxiv. 2021 doi: 10.1101/2021.11.08.21265380. published online Nov 8. (preprint). - DOI - PMC - PubMed
1. Li KK, Woo YM, Stirrup O, et al. Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface. J Infect. 2021;83:96–103. - PMC - PubMed
1. Carr EJ, Wu M, Harvey R, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021;398:1038–1041. - PMC - PubMed